Engagement summary
Client Background
Axonics was a publicly traded medical-device company that developed sacral neuromodulation systems, ultimately acquired by Boston Scientific in 2024.
Engagement Scope
R&M supported Axonics across SOX 404 program design and testing through multiple fiscal years, ASC 326 CECL implementation, the Contura acquisition purchase accounting, and ongoing SEC compliance.
Services Provided
- SOX 404 control design, documentation, and testing
- ASC 326 CECL adoption and methodology
- ASC 805 purchase accounting — Contura acquisition
- Professional consulting and SEC compliance
